Eli Lilly announced that a combination therapy pairing its experimental drug eloralintide with a low dose of tirzepatide demonstrated superior weight loss outcomes compared to tirzepatide monotherapy in a Phase 2 clinical trial. The company presented the findings at a medical conference, marking a significant development in obesity treatment research.
In the 48-week trial, patients receiving the highest dose of the combination regimen achieved average weight loss of 23.3%, equivalent to approximately 54 pounds. This compared favorably to the 14.8% weight loss, or roughly 34.4 pounds, observed in patients taking only the higher dose of tirzepatide. Treatment with eloralintide alone resulted in 12.3% weight loss, around 28.6 pounds on average. The combination approach also demonstrated improvements in blood sugar control, with A1C reductions reaching 2.9% on average, surpassing the 2.4% reduction from tirzepatide monotherapy and the 1.4% from the amylin drug alone.
Eloralintide targets amylin, a pancreatic hormone involved in appetite regulation and satiety, while tirzepatide addresses two additional gut hormones, GLP-1 and GIP. Lilly’s hypothesis that simultaneously engaging all three hormone pathways could amplify appetite suppression and weight loss was confirmed in the trial data. The company indicated that it intends to develop a co-formulation allowing single-injection administration of both compounds and plans to initiate Phase 3 testing by the end of 2026.
Toleration emerged as a consideration, with higher discontinuation rates due to adverse effects observed in combination therapy groups. Discontinuation rates ranged from 10.8% to 27% depending on dosing, compared with 2.9% for tirzepatide monotherapy. Gastrointestinal side effects were the most commonly reported issues, typically mild to moderate in severity and concentrated during dose escalation phases. Company executives noted that dosing strategies would be refined for Phase 3 trials based on Phase 2 learnings, with expectations that the final formulation would demonstrate favorable efficacy-tolerability balance.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI